Compare Neurocrine Biosciences Inc (NBIX) vs SMX Security Matters plc (SMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs SMX Security Matters plc — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while SMX Security Matters plc trades at $17.92 (market cap $19.09M). The key difference: Neurocrine Biosciences Inc is far larger — about 826.1× SMX Security Matters plc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals.
| NBIX | SMX | |
|---|---|---|
Market Cap | $15.77B | $19.09M |
Sector | Health | Technology |
52-Week High | $185.50 | $74.08K |
52-Week Low | $123.10 | $12.87 |
Enterprise Value | $15.78B | -$12.23M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
SMX trades at $17.88, down 8.21% on the day, with a bullish technical signal from moving averages and oscillators. The company reported a net loss of $169.18 million for 2025, with negative cash flow from operations but positive net cash flow due to financing. Recent news highlights expansion of its digital material passport platform for plastics and precious metals, targeting sustainability and supply chain verification markets.
The outlook hinges on commercialization success amid steep losses. Opportunities exist in regulatory tailwinds for recycled materials, but high cash burn and negative ROE pose significant risks. Investor sentiment is cautiously optimistic due to technology potential, yet profitability remains a distant milestone.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
